Business Wire

CA-KURION

Del
Kurion Selected by Japan’s Ministry of Economy, Trade and Industry to Demonstrate Tritium-Removal Technology

Kurion, Inc., an innovator in nuclear and hazardous waste management, announced that it received a grant of one billion Japanese Yen (approximately 10 million USD) from Japan’s Ministry of Economy, Trade and Industry (METI ) to demonstrate the company’s cost-effective tritium-removal technology for possible deployment at Fukushima. Kurion’s Modular Detritiation System is one of three technologies approved for the “Demonstration Project for Verification Tests of Tritium Separation Technologies” from a field of 182 submissions . Kurion has played an active role in the cleanup at Fukushima since the development of its cesium-adsorption system in 2011 in the weeks following the earthquake and tsunami that devastated the site; this agreement represents the company’s fourth major project to assist the site.

“We are honored to be selected by the Ministry of Economy, Trade and Industry to demonstrate the economical effectiveness of Kurion’s detritiation technology,” said Kurion Founder and President John Raymont. “We have assembled a team of globally renowned experts to monitor the project and attest to the efficacy, scalability and economics of our technology to successfully treat the tritium accumulating at the Fukushima site. The demonstration project will begin immediately and will take place at Kurion’s detritiation facility.”

The Tritium Challenge at Fukushima

Today there are more than 400,000 tons of contaminated water stored in tanks at Fukushima, a number that is growing at the rate of 400 tons per day. Submissions for the tritium-removal project required the ability to treat 800,000 tons of tritiated water. TEPCO has already installed two types of systems to remove contaminants from the stored water: Kurion’s Mobile Processing System (KMPS ) and the Multi-nuclide Removal Systems known as ALPS .

While the KMPS and ALPS remove contaminants in the water, they do not remove tritium. That is because the decontamination of tritium (T) is particularly problematic: it is a special form of hydrogen that forms tritiated water (HTO vs. H2 O), which does not lend itself to removal by conventional technologies. This is due to the fact that the water molecule itself is modified, rather than the contaminant being carried along in water in suspended or dissolved form. As a result, tritiated water is particularly difficult to treat and can spread easily if it escapes into the environment.

Raymont added, “We recognize the urgency of the situation as water accumulates at the Fukushima site. While the specified completion date for the project is March 2016, it is our goal to accelerate the demonstration project and provide the necessary data by the end of 2015 to enable the METI, TEPCO and the Japanese people to make an informed decision about the tritium contamination at Fukushima.”

At the Fukushima site, space is another constraint. Kurion’s modular system has a small footprint, and it can scale rapidly to process the water in the required time frame to minimize additional storage requirements.

“The Kurion approach for treating tritium at Fukushima offers TEPCO an unlikely option and benefit: it creates a significant Hydrogen feedstock for Japan’s ‘hydrogen economy’ and supports the METI 2015 Hydrogen Initiative to establish hydrogen as an energy source for cars. The 800,000 tons of tritiated water at Fukushima would generate about 90,000 tons of H2 ,” said Raymont.

The Challenge of Economically Removing Tritium

The industrial process of removing tritium from water has historically focused on cleaning highly contaminated “heavy water” for recycling back into nuclear reactors, such as the process used for CANDU reactors. However, this technology is prohibitively expensive for use with light water reactors. Kurion’s Modular Detritiation System is a unique, patent-pending technology based on advances to the proven heavy water Combined Electrolysis Catalytic Exchange (CECE) process. The system converts tritiated water (HTO) to gaseous Hydrogen (H2 ), gaseous Oxygen (O2 ) and gaseous Tritium (HT); it then separates Tritium (T) for stabilization, enabling the safe disposition of the clean H2 and O2 gas streams (e.g., resold as chemical feedstock, flared to atmosphere, or recombined as H2 O).

“Kurion has performed extensive tests on our Modular Detritiation System using a simulant of the contaminated water at the same tritium concentration levels found at the Fukushima site,” said Dr. Gaëtan Bonhomme, Kurion’s Chief Technology Officer, who led the demonstration of the detritiation technology. “These tests on tritiated water indicate that Kurion’s system successfully isolates the tritium, significantly reduces the volume of final waste, and can scale to meet the challenge at Fukushima.”

Many detritiation solutions have difficulty achieving an adequate decontamination factor when starting at low contamination factors. Kurion achieves this by adjusting certain parameters of its equipment and internal recycles. As a result, Kurion can uniquely modify the system’s goals to meet customer objectives. The system does not produce any liquid waste and concentrates the tritium so the small volume can be easily dispositioned.

Global Applications for Tritium-Removal in Commercial Nuclear Sector

Bill Gallo, Kurion CEO, added, “Kurion’s detritiation technology also has possible long-term applications for commercial nuclear plants. As we mature this technology, our goal is to provide operators of light pressurized water reactors an economical alternative to the controlled release of tritium into the environment and allow them to achieve a zero-liquid release status. This would eliminate community concerns and strengthen nuclear energy’s status as a clean energy source.”

ABOUT KURION

Kurion creates technology solutions to access, separate and stabilize nuclear and hazardous waste to isolate it from the environment. Kurion’s suite of technologies and engineering capabilities offer a platform to address the most-challenging nuclear and hazardous waste sites worldwide. Founded in 2008, Kurion is backed by leading energy investors Lux Capital , Firelake Capital Management and Acadia Woods Partners . The company is headquartered in Irvine, Calif., and has facilities in Richland, Wash., Houston, Texas, Loveland, Colo., Idaho Falls, Idaho, and Tokyo, Japan. For more information, please visit www.kurion.com .

Contact:

For Kurion, Inc.
Katie Wood Znameroski
Phone: +1 (650) 801-7952
Fax: +1 (650) 508-8336
katie.wood@zenogroup.com
www.kurion.com

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release

Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi

IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release

IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release

Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s

NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release

NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates

Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release

As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye